QLife (QLIFE) Q3 2025 earnings summary

Executive summary

• Revenue for Q3 2025 was KSEK 65, up from KSEK 39 in Q3 2024, driven by sales of Egoo.Health devices and capsules.

• EBITDA improved to KSEK -6,398 from KSEK -27,151 year-over-year; net loss narrowed to KSEK -6,764 from KSEK -28,087.

• The company is progressing with a merger with Hipro, aiming to create an integrated diagnostics powerhouse with global reach.

• Strategic focus includes regulatory submissions for self-testing products and expansion into new biomarker tests.

Financial highlights

• Revenue for Q3 2025: KSEK 65 (Q3 2024: KSEK 39); YTD revenue: KSEK 275 (YTD 2024: KSEK 39).

• EBITDA for Q3 2025: KSEK -6,398 (Q3 2024: KSEK -27,151); net loss: KSEK -6,764 (Q3 2024: KSEK -28,087).

• Cash reserve at end of Q3 2025: KSEK 2,811 (Q3 2024: KSEK 3,066).

• Total cash flow in Q3 2025: KSEK 2,336 (Q3 2024: KSEK 2,979).

• Shareholders' equity at Q3 2025: KSEK -5,269 (Q3 2024: KSEK 199).

Outlook and guidance

• The merger with Hipro is expected to be finalized by the end of 2025, pending regulatory approvals.

• Focus on regulatory submissions for Egoo PHE self-test in the UK and EU, and clinical trials for new biomarker tests.

• Anticipates growth in decentralized healthcare and direct-to-consumer diagnostics.